AmorChem invests in projects at the Personalized Cancer ImmunoTherapy Program

AmorChem is very proud to announce that it has entered into an agreement with Hôpital Maisonneuve-Rosemont (HMR) and Univalor to participate in the financing of R&D activities at the Personalized Cancer ImmunoTherapy Program (PCITP). This is the second AmorChem financing for the PCITP, the first being the product of an existing agreement with HMR, the Université of Montréal (UdeM), Institute for Research in Immunology and Cancer and its Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR).